Godavari Biorefineries Limited Reports Q3 & 9M FY26 Results
Key Highlights (Consolidated – Q3 FY26):
* Total Income: Rs 461.9 crore (vs. Rs 450.8 crore in Q3 FY25)
* EBITDA: Rs45.1 crore (up 13.8% YoY)
* EBITDA Margin: 9.8% (vs. 8.8% in Q3 FY25)
* PBT (before exceptional items): Rs21.4 crore (up 152.2% YoY)
9M FY26 Performance Snapshot:
* Total Income: Rs1,430.2 crore
* EBITDA: Rs47.2 crore (vs. Rs(1.4) crore in 9M FY25)
* PBT (before exceptional items): Rs(31.2) crore (vs. Rs(97.3) crore in 9M FY25)
Segment Highlights – Q3 FY26:
* Bio-based Chemicals EBITDA: Rs10.9 crore (up 76.7% YoY)
* Sugar & Cogeneration EBITDA: Rs32.1 crore (up 28.1% YoY)
* Ethanol EBITDA: Rs4.2 crore
Commenting on the results, Samir Somaiya, Chairman & Managing Director, said:
“Q3 FY26 marked a quarter of significantly improved profitability, driven by operating leverage and disciplined execution. EBITDA grew approximately 14% year-on-year to Rs45.1 crore, while PBT before exceptional items surged 152% year-on-year to RRs 21.4 crore. Our margins also expanded meaningfully as we focus more on high-margin segments, reinforcing the company’s strategic direction.
Finance costs for the quarter declined by 46% year-on-year, in line with our strategy to improve cash flows to fuel growth. The Bio-based Chemicals segment continued to support profitability, with specialty chemicals contributing 62% of the basket in 9M FY26, and we expect this share to rise further as we scale high-value offerings.
A key highlight during the period was the grant of a U.S. patent for our novel anti-cancer molecule targeting triple-negative breast cancer, underscoring the strength of our R&D capabilities and commitment to innovation-led growth. In parallel, our DME-to-CO? technology initiative is progressing well, with pilot plant activities underway.
We recently collaborated with Synthomer, to develop bio-based alternatives to fossil-based monomers. Through this collaboration, Synthomer is commercialising bio-based butyl acrylate using GBL’s bio-based butanol, accelerating the industry’s transition to sustainable raw materials and reflecting our continued focus on sustainability, green chemistry, and next-generation energy solutions. We are also encouraged by strong traction in our consumer segment, with our Jivana brand crossing the Rs 100 crore revenue milestone in the first nine months of FY26, reinforcing our strategy to scale the retail platform alongside our industrial businesses. Our fungible grain-based ethanol capacity will be commissioned in Q1 FY27, positioning us to benefit from the restoration of the ethanol blending program and incremental demand from maize-based capacities.
These initiatives, along with ongoing debottlenecking and investments in technology, are strengthening our ability to manage seasonality while improving efficiency. Overall, our continued focus on high-potential bio-based specialty chemicals, capacity optimization, and sustainability-led innovation positions us well to drive long-term growth and value creation.”
Above views are of the author and not of the website kindly read disclaimer
